The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC).
A. M. Gonzalez-Angulo
Consultant or Advisory Role - Novartis (U)
Research Funding - Novartis
M. C. Green
No relevant relationships to disclose
J. L. Murray
No relevant relationships to disclose
S. L. Palla
No relevant relationships to disclose
K. H. Koenig
No relevant relationships to disclose
A. M. Brewster
No relevant relationships to disclose
V. Valero
No relevant relationships to disclose
N. K. Ibrahim
No relevant relationships to disclose
S. L. Moulder
No relevant relationships to disclose
J. K. Litton
Research Funding - Novartis
D. J. Crawford
No relevant relationships to disclose
P. R. Flores
No relevant relationships to disclose
M. J. Dryden
No relevant relationships to disclose
W. F. Symmans
No relevant relationships to disclose
S. H. Giordano
No relevant relationships to disclose
L. Pusztai
No relevant relationships to disclose
A. Buzdar
No relevant relationships to disclose
G. B. Mills
Consultant or Advisory Role - Novartis (U)
Research Funding - Novartis
G. N. Hortobagyi
No relevant relationships to disclose
F. Meric-Bernstam
Research Funding - Novartis